Behzad Aghazadeh Acquires Shares in Whitehawk Therapeutics
On June 12, 2026, insider Behzad Aghazadeh purchased 38,040 shares of Whitehawk Therapeutics.
Key Points
- Behzad Aghazadeh bought 38,040 shares of Whitehawk Therapeutics, Inc. on June 12, 2026.
- Whitehawk Therapeutics (NasdaqCM: WHWK) trades at $4.16 with a market cap of about $202.8 million.
- Analysts from Citizens and Jones Trading have buy ratings with price targets of $8.00 and $7.00, respectively.
Insider Behzad Aghazadeh made a significant move by purchasing 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) on June 12, 2026. This acquisition adds to the interest in the company's stock, which trades at around $4.16 per share.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders, including Behzad Aghazadeh, acquired 38,040 shares each in Whitehawk Therapeutics. This purchase was not part of a pre-planned trading program, indicating a direct interest in the company's future.
Other Institutional Activity in Whitehawk Therapeutics
Several institutional investors hold significant positions in Whitehawk Therapeutics. QVT Financial LP maintains 4,615,709 shares valued at approximately $15.9 million. Orbimed Advisors LLC holds 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC has 3,700,000 shares valued at roughly $12.8 million. Acuta Capital Partners, LLC and Avoro Capital Advisors LLC hold 3,410,402 and 2,849,402 shares, valued at $11.8 million and $9.8 million, respectively.
Whitehawk Therapeutics Stock Snapshot
Shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) are trading near $4.16. The company has a market capitalization of approximately $202.8 million. It is not currently profitable, as indicated by its negative forward P/E ratio. The stock's 52-week range is between $1.57 and $5.50, with a 50-day moving average of $4.15 and a 200-day moving average of $2.98. The company has a strong liquidity position with a current ratio of 11.36 and a quick ratio of 11.13.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a buy rating and a price target of $8.00. Similarly, Jones Trading started coverage with a buy rating and a $7.00 price target on December 22, 2025. The overall analyst consensus is a buy, with a mean target price of $6.50 based on four analyst opinions.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics. Headquartered in Morristown, New Jersey, the company specializes in creating next-generation antibody drug conjugates (ADCs) to treat cancer. Led by CEO Dr. David J. Lennon, Whitehawk employs 29 people and continues to innovate in the cancer treatment space.
Bottom Line
Behzad Aghazadeh's recent purchase of Whitehawk Therapeutics shares highlights ongoing interest in the company's potential. With a strong liquidity position and recent analyst buy ratings, Whitehawk remains a key player to watch in the biotechnology sector. Remember, insider transactions like these are disclosed after the fact and may not reflect the current state of holdings.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.